If this is the case, when SMA patients are treated with a splicing-modulation therapy, determining the expression level of the exon 7a-containing SMN transcript may be essential to avoid unexpected off-target effects of the therapeutic compounds. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.